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Purpose: The aim of this study was to determine the prevalence and risk factors of ex-
tended spectrum beta-lactamase (ESBL)-producing microorganisms in urinary tract 
infection.
Materials and Methods: A total of 2,312 patients older than 25 years and diagnosed 
from January 2007 to December 2009 as having urinary tract infection were studied. 
The prevalence of ESBL-producing microorganisms including Escherichia coli and the 
antimicrobial susceptibility of E. coli were examined. Univariate analyses were per-
formed with gender, age, inpatient status, previous hospitalization, recent history of 
urinary catheterization, recent exposure to specific antibiotics, and past history of ur-
ogenital organ operation as risk factors for the emergence of ESBL-producing micro-
organisms. Then, multivariate analysis was performed with all significant variables.
Results: In outpatient urinary tract infection, the antimicrobial susceptibility of E. coli
to each of the third-generation cephalosporins, cefotaxime, ceftazidime, and ceftriax-
one, was 87.6%, 93.4%, and 87.7%, respectively, and the prevalence of ESBL-producing 
E. coli was 12.1%. In inpatient urinary tract infection, the susceptibility of E. coli was 
78%, 84.5%, and 76.9%, respectively, and the prevalence was 23.1%.
Conclusions: The overall prevalence of ESBL-producing microorganism was 12.6% and 
the risk appeared to be increased in cases with a previous hospitalization, a recent his-
tory of urinary catheterization, inpatient status, cefaclor medication, cefminox admin-
istration, and female gender.
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INTRODUCTION
Since their development in the 1960s, fluoroquinolones 
have been frequently prescribed for infectious disease. 
Together with trimethoprim-sulfamethoxazole (TMP-SMZ), 
fluoroquinolones are included among the antibiotics rec-
ommended by the Infectious Disease Society of America 
(IDSA) for urinary tract infection [1]. Despite this, resist-
ance to TMP-SMZ and fluoroquinolones has been reported 
in urinary tract infection worldwide [2-5]. Ampicillin has 
been frequently used for urinary tract infection as an alter-
native drug owing to its activity against gram-negative 
microorganisms. Nonetheless, as acquired resistance to 
beta-lactam class antibiotics was reported [6], cephalos-
porins stable to beta-lactamase were developed, and thus 
the choice of antibiotics for urinary tract infection was wid-
ened [7,8]. However, after the report of extended spectrum 
beta-lactamase (ESBL)-producing organisms in 1983 in 
Germany, anxiety over the emergence of bacteria resistant 
to cephalosporins has been growing more and more [9].
　According to the beta-lactamase classification by Bush 
et al, ESBL belongs to group 2be and is an enzyme that in-
activates extended spectrum beta-lactam antibiotics such 
as cefotaxime, ceftazidime, and aztreonam [10]. The preva-Korean J Urol 2010;51:492-497
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TABLE 1. Comparison of antimicrobial susceptibilities between 
O-UTI and I-UTI
Antimicrobial susceptibility of Escherichia coli
O-UTI 
n (%)
I-UTI 
n (%)
OR   95% CI
a
A/C 667 (66.0) 151 (54.5) 1.63  1.24-2.13
CZ 769 (76.1) 192 (69.3) 1.41  1.05-1.89
CTX 885 (87.6) 216 (78.0) 1.99  1.42-2.81
CT 994 (98.4) 258 (93.1) 4.57  2.32-9.02
CTZ 943 (93.4) 234 (84.5) 2.59  1.71-3.89
CFT 887 (87.8) 213 (76.9) 2.05  1.49-2.89
CFX 848 (84.0) 192 (69.3) 2.32  1.71-3.15
CF 688 (68.1) 160 (57.8) 1.56  1.19-2.05
IP 1,003 (99.3) 271 (97.8) 3.17  1.05-9.51
T/S 619 (61.3) 141 (50.9) 1.53  1.17-1.99
ESBL 122 (12.1) 64 (23.1) 2.19  1.56-3.07
O-UTI: outpatient urinary tract infection, I-UTI: inpatient uri-
nary tract infection, OR: odds ratio, CI: confidence interval, A/C:
ampicillin/clavulanate, CZ: cefazolin, CTX: cefotaxime, CT: cefo-
tetan, CTZ: ceftazidime, CFT: ceftriaxone, CFX: cefuroxime, CF:
ciprofloxacin, IP: imipenem, T/S: trimethoprim/sulfamethox-
azole, ESBL: extended spectrum beta-lactamase, 
a: p＜0.01 ex-
cept for imipenem (p=0.047)
lence of ESBL-producing bacteria is gradually on the rise 
[11].
　Therefore, we investigated the current situation of re-
sistance of Escherichia coli to antibiotics and the preva-
lence of ESBL-producing bacteria in patients treated for 
urinary tract infection at our hospital as outpatients and 
as inpatients. In addition, by examining the past history 
of antibiotic administration, the past history of catheter-
ization, and the past history of urological treatments and 
assessing their effects on the emergence of ESBL-produc-
ing bacteria, we made efforts to establish measures to pre-
vent the emergence of resistant bacteria.
MATERIALS AND METHODS
1. The subjects and the methods
The clinical characteristics of 2,312 patients older than 25 
years and diagnosed from January 2007 to December 2009 
as having urinary tract infection were assessed by examin-
ing the patients’ medical records.
　Patients diagnosed as having urinary tract infection in 
the outpatient clinic or emergency room or patients diag-
nosed within 48 hours after hospitalization were classified 
as having outpatient urinary tract infection (O-UTI), and 
patients diagnosed during the hospitalization period were 
classified as having inpatient urinary tract infection 
(I-UTI).
　The diagnosis of urinary tract infection was based on the 
standard of the Centers for Disease Control and Prevention 
(CDC) of detection of 10
5 bacterial colonies/ml by urine cul-
ture with more than one of the following symptoms or signs: 
fever higher than 38
oC, tenderness in the suprapubic area, 
painful urination, urgency, and frequency.
　The automatic identification and sensitivity Microscan 
system (Baxter Diagnostics Inc, USA) was used to identify 
the bacteria, and the minimal inhibitory concentration 
(MIC) was measured by the micro broth dilution method. 
At that time, ampicillin/clavudaric acid, cefazolin, cefotax-
ime, ceftazidime, ceftriaxone, cefotetan, cefuroxime, cipro-
floxacin, imipenem, and trimethoprim/sulfamethoxazole 
were used as antibiotics.
　I-UTI, previous hospitalization, female gender, old age, 
previous antimicrobial medication, Foley catheterization, 
and urogenital organ operation were considered as risk fac-
tors for the appearance of ESBL-producing bacteria.
　Past history of hospitalization was defined as cases hos-
pitalized for more than 1 day before the time of the diag-
nosis of urinary tract infection. Past history of use of anti-
biotics was defined as cases administered at least one anti-
biotic for more than one day before the time of the diagnosis 
of urinary tract infection. At that time, 10 antibiotics in-
cluding quinolones, beta lactams, and cephalosporins that 
are known to be effective against gram-negative micro-
organisms were examined. We defined a past history of 
Foley catheterization as cases with catheterization for 
more than 3 days before the diagnosis of urinary tract in-
fection [12].
2. Statistics
SPSS
Ⓡ version 12.0 (SPSS Inc. Chicago, IL, USA) was used, 
and p＜0.05 was considered to be statistically significant.
　Factors suspected to be risk factors for the emergence of 
ESBL-producing bacteria were analyzed by univariate 
analysis, Kruskal Wallis test, and chi-square test. After-
ward, a multivariate analysis was performed with all sig-
nificant variables, and the odds ratio was calculated with 
a confidence interval of 95%.
RESULTS
1. Epidemiology of ESBL-producing bacteria in UTI
Among the total 2,312 patients with urinary tract infection, 
291 patients (13.02% of the total) were infected with 
ESBL-producing bacteria. The incidence of ESBL-produc-
ing E. coli was shown to be 14.5%; it was 12.1% in O-UTI 
(122/1010) and 23.1% in I-UTI (64/277), and thus the risk 
of development of ESBL-producing E. coli was 2 times high-
er in I-UTI (Table 1).
2. Antimicrobial susceptibility
In O-UTI and I-UTI, susceptibility to ciprofloxacin, one of 
the fluoroquinolones, was 68.1% and 57.8%, respectively, 
and was lower than that to cephalosporins. Among the 
cephalosporins, susceptibility to cefotetan, one of the sec-
ond-generation cephalosporins, was the highest. However, 
lower susceptibility to cefuroxime, one of the second-gen-
eration cephalosporins, than to other third-generation 
cephalosporins was shown. Among the third-generation 
cephalosporins, susceptibility of E. coli was highest to 
ceftazidime. Susceptibility to ceftazidime in O-UTI and Korean J Urol 2010;51:492-497
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TABLE 2. Antibiotic susceptibility patterns of ESBL-producing
E. coli
Antibiotic susceptibility (%)
Ampicillin/Clavulanate 3.8
Cefazolin 1.3
Cefotetan 95.9
Cefotaxim 3.8
Ceftazidime 42.3
Ceftriaxone 3.8
Ciprofloxacin 28.2
Imipenem 98.7
TMP/SMX 42.3
ESBL: extended spectrum beta-lactamase, TMP/SMX: trimetho-
prim/sulfamethoxazole
TABLE 3. Patient characteristics and epidemiological and clinical
variables associated with ESBL-producing pathogens (univariate
analysis)
ESBL
(n=291)
Non-ESBL 
(n=2,021)
p-value
Mean age±SD (years)
a 65.82±12.74 64.74±14.15 0.183
Inpatient origin (%)
b 46.73 31.89 ＜0.001
Previous hospitalization
  (%)
b
21.31 8.11 ＜0.001
Sex (female%)
b 78.69 70.46 0.004
Operation history of the
  urinary tract (%)
b
6.87 10.47 0.055
Foley catheterization (%)
b 12.71 6.64 ＜0.001
Previous medication (%)
b
CFC 12.02 8.43 0.043
CDN 0 0.64 0.166
CFX 2.02 15.16 0.561
CXV 14.43 10.85 0.045
CTXV 1.03 0.54 0.767
CPDX 6.19 5.95 0.875
CZXV 5.84 5.80 0.949
CTRV 12.03 9.96 0.296
FXV 5.50 7.88 0.161
CF 17.18 14.97 0.340
LVF 2.06 2.68 0.571
AUG 7.90 8.23 0.809
ESBL: extended spectrum beta-lactamase, SD: standard devia-
tion, CFC: cefaclor, CDN: cefdinir, CFX: cefuroxime, CXV: cefmi-
nox, CTXV: cefotaxime, CPDX: cefpodoxime, CZXV: ceftazidime,
CTRV: ceftriaxone, FXV: flomoxef, CF: ciprofloxacin, LVF: levo-
floxacin, AUG: ampicillin/clavulanate, 
a: by Kruskal Wallis test,
b: by chi-square test
TABLE 4. Multivariate analysis of relative risks associated with
ESBL-producing pathogens
Risk factors OR 95% CI p-value
Inpatient origin 1.71 1.308-2.235 ＜0.001
Previous hospitalization 2.49 1.762-3.505 ＜0.001
Sex (female) 1.44 1.062-1.951 0.019
Foley catheterization 2.38 1.593-3.567 ＜0.001
CFC 1.68 1.126-2.510 0.011
CXV 1.54 1.068-2.210 0.021
ESBL: extended spectrum beta-lactamase, OR: odds ratio, CI: 
confidence interval, CFC: cefaclor, CXV: cefminox
I-UTI was 93.4% and 84.5%, respectively. Generally, sus-
ceptibility of E. coli to antibiotics was lower in I-UTI than 
in O-UTI (Table 1). On the other hand, the susceptibility 
of ESBL-producing E. coli to all antibiotics, except imipe-
nem and cefotetan, was lower than 50% (Table 2).
3. Risk factors and odds ratios
Table 3 shows the results of the univariate analysis of risk 
factors that may exert effects on the emergence of ESBL- 
producing bacteria. I-UTI, previous hospitalization, fe-
male gender, past history of Foley catheterization, and past 
history of exposure to specific antibiotics were revealed as 
statistically significant variables. Among antibiotics, only 
the second-generation cephalosporin drug cefaclor in oral 
form and the second-generation cephalosporin cefminox in 
injection form were statistically significant.
　Table 4 shows the relative risks in association with the 
emergence of ESBL-producing bacteria analyzed by multi-
variate analysis performed with all significant variables in 
the univariate analysis. Previous hospitalization and past 
history of catheterization were associated with relative 
risks for the emergence of ESBL-producing bacteria of 2.5 
and 2.4, respectively, followed by (in order) I-UTI, cefaclor 
medication, cefminox administration, and female gender.
DISCUSSION
The development of antibiotics has contributed greatly to 
reducing mortality caused by infection; nonetheless, as the 
use of antibiotics becomes generalized, the vicious circle of 
the development of new antibiotics and the emergence of 
resistant bacteria cannot be severed. In fact, according to 
an epidemiological study conducted by the National 
Nosocomial Infections Surveillance (NNIS), the resistance 
rate of most bacteria to antibiotics has increased [13].
　Comparison of two studies conducted on ambulatory pa-
tients well explains the increasing resistance of E. coli to 
TMP-SMZ and ciprofloxacin in America [4,5]. In the report 
of the European Antimicrobial Resistance Surveillance 
System (EARSS), similarly, in most European countries, 
the prevalence of E. coli resistant to fluoroquinolones, the 
third-generation cephalosporins, and aminoglycosides is 
on the increase every year [3].
　In Korea, according to the study reported by Ryu et al, 
a trend for a reduction in sensitivity of E. coli to the third- 
generation cephalosporins and fluoroquinolones was ob-
served, and E. coli resistance to antibiotics was greater in 
I-UTI [14]. An increase in resistance to antibiotics in O-UTI 
has been shown already in other Korean studies [15-17].
　We investigated the antimicrobial susceptibilities of E. 
coli in I-UTI compared with O-UTI. Because of the possi-Korean J Urol 2010;51:492-497
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bility of contamination from a nosocomial component, we 
used the term ‘outpatient’ instead of ‘community-acquired.’ 
The sensitivity of E. coli to cephalosporins and fluoro-
quinolones was lower in I-UTI. In contrast, the emergence 
of ESBL-producing bacteria was observed to be higher in 
I-UTI (Table 1). In O-UTI, sensitivity of E. coli to the 
third-generation cephalosporins did not show a great dif-
ference from the studies reported in 2008 by Lee [17]; none-
theless, in comparison with other previous studies, slightly 
reduced patterns were observed [15,16]. In comparison 
with Europe, concerning the second-generation cepha-
losporin drug cefuroxime, sensitivity was comparable to 
that in a multinational study conducted by Naber et al [18]. 
Nonetheless, in comparison with the 2008 EARSS report, 
the sensitivity of E. coli to the entire class of third-gen-
eration cephalosporins was observed to be lower, excluding 
Bulgaria (29%) and Turkey (42%) [3].
　The current situation of resistance to antibiotics has 
reached a serious point In urinary tract infection, and pres-
ently, multidrug-resistant bacteria including ESBL-pro-
ducing bacteria can be readily encountered in clinics. 
Antibiotics that can be used for the treatment of multi-
drug-resistant bacteria including ESBL-producing bac-
teria In urinary tract infection are limited [19]. In our 
study, similarly, excluding imipenem and cefotetan, anti-
biotics with sensitivity higher than 50% to ESBL-produc-
ing E. coli were absent (Table 2). In addition, infection with 
ESBL-producing bacteria raises mortality, and it not only 
prolongs hospital stay but also increases relative treat-
ment costs [20]. Therefore, it is very important to assess the 
risk factors for the emergence of multidrug-resistant bac-
teria, including ESBL-producing bacteria, and to provide 
means to prevent such resistance.
　Recent studies showed that the emergence of ESBL-pro-
ducing bacteria is more frequent in patients with a past his-
tory of hospitalization, a past history of exposure to anti-
biotics, a past history of catheterization, and a past history 
of urogenital surgery [21-23]. In the present univariate 
analysis, female gender, I-UTI, recent history of hospital-
ization, recent history of Foley catheterization, and recent 
exposure to specific antibiotics were observed to be asso-
ciated with the emergence of ESBL-producing bacteria 
(Table 3). In the multivariate analysis, recent hospital-
ization was shown to be the greatest risk factor, followed 
by (in order) Foley catheterization, I-UTI, exposure to cefa-
clor, exposure to cefminox, and female gender (Table 4). 
Rodriguez-Bano et al reported in a case-control study con-
ducted on 147 patients with O-UTI that the strongest risk 
factor for the emergence of ESBL-producing E. coli was a 
past history of hospitalization within the recent 1 year 
(odds ratio, 18.2; 95% confidence interval, 1.9 to 30.1) [24]. 
In our study, similarly, the probability of infection with 
ESBL-producing E. coli was higher in patients with a re-
cent history of hospitalization than in patients without a 
history by approximately 2.5 times (Table 4). This suggests 
that blocking of infection within hospitals could reduce the 
prevalence of ESBL-producing bacteria and could lower 
the spread to communities. Thus, efforts to reduce the op-
portunities for inpatient infection with ESBL-producing 
bacteria should be considered very important. Siegel et al 
recommended that to block the spread of multidrug-resis-
tant bacteria within hospitals, hospitals should restrict 
contact with patients infected with multidrug-resistant 
bacteria internally and provide detergents containing alco-
hol in the area and require their use [25]. In addition, they 
mentioned that hand hygiene education for medical staff 
and guardians should be required. Furthermore, Siegel et 
al emphasized the need to monitor the trend of multi-
drug-resistant bacteria by routine bacterial culture and al-
so to establish organized report systems.
　A past history of exposure to a specific antibiotic may be 
another risk factor for the emergence of ESBL-producing 
bacteria, and this topic is currently an active research area. 
Calbo et al reported the risk factors of exposure to the sec-
ond-generation cephalosporins in oral form and the sec-
ond-generation cephalosporin drug cefuroxime in injection 
form [21]. In our study, similarly, the second-generation 
cephalosporin drug cefaclor in oral form and the sec-
ond-generation cephalosporin drug cefminox in injection 
form were shown to be risk factors. Among ESBL patients, 
the percentages of patients already exposed to these drugs 
were 12.2% and 14.4%, respectively. The percentage of pa-
tients already exposed to ciprofloxacin, one of the fluo-
roquinolones, was 17.2%; nonetheless, it was not asso-
ciated with the emergence of ESBL-producing bacteria. 
Goossens et al explained the association of the level of use 
of antibiotics with bacteria acquiring resistance and em-
phasized the adequate use of antibiotics [26]. In fact, it has 
been reported that the appropriate use of antibiotics 
against gram-negative bacteria decreases the frequency of 
multidrug-resistant bacteria [25]. On the other hand, in 
clinics, prescription of antibiotics empirically for pyuria in 
asymptomatic bacteriuria patients or catheterized pa-
tients is seen occasionally, and the IDSA suggests the 
standard of prescription of antibiotics for such patients 
[27]. Therefore, to prevent the emergence of multi-
drug-resistant bacteria in urinary tract infection, efforts 
should be made to strictly observe the indications for the 
administration of antibiotics and to use antibiotics appro-
priately for a minimal period through culture for cases re-
quiring antibiotics.
　Foley catheterization is well known to be a risk factor for 
urinary tract infection. About 20% of urinary tract in-
fection associated with Foley catheterization occurs due to 
unskilled sterilization techniques during the insertion of 
the catheter [28]. Infection may occur due to contamination 
of the collecting system through the lumen of the catheter 
[29]. Other cases have been reported to occur through the 
biofilm formed between catheter and the urethral mucosa 
[30]. Some reports emphasized that Foley catheterization 
may play an important role as a risk factor for the appear-
ance of ESBL-producing bacteria [22]. In our study, sim-
ilarly, the risk of emergence of ESBL-producing bacteria 
appeared to be approximately 2.4 times higher in patients Korean J Urol 2010;51:492-497
496 Lee et al
with Foley catheterization (Table 4). Therefore, un-
necessary Foley catheterization should be avoided in pa-
tients with urinary tract infection to prevent the emer-
gence of ESBL-producing bacteria. If unavoidable, Foley 
catheterization should be performed by use of sterile tech-
niques, and a closed drainage system should be applied 
during the minimal indwelling period.
　Female gender appeared to be a risk factor for the emer-
gence of ESBL-producing bacteria, and the proportion of 
women was about 8% higher in the ESBL group than in the 
non-ESBL group, although some studies have shown no 
statistical difference in gender or a slightly higher in-
cidence of ESBL-producing bacterial infection in men 
[21-24]. Because many studies had a relatively small scale 
and were conducted retrospectively in limited age groups, 
large, prospective clinical studies with all age groups will 
be required to minimize the selection bias.
　A past history of urogenital surgery, regardless of the 
type of the surgery, had no association with ESBL-produc-
ing bacterial infection in this study. Therefore, further clin-
ical studies are needed because the fraction of the ESBL 
group with a urogenital operative history was too low to 
avoid the error of false generalization.
CONCLUSIONS
The total prevalence of ESBL-producing microorganisms 
in urinary tract infection was approximately 13%. In 
O-UTI and I-UTI, the prevalence of ESBL-producing E. coli 
was 12.1% and 23.1%, respectively. The risk appeared to 
be increased in cases with I-UTI, previous hospitalization, 
a history of Foley catheterization, previous exposure to spe-
cific antibiotics, and female gender. Among the risk factors, 
a past history of hospitalization appeared to be the greatest 
risk factor.
　Therefore, to prevent the spread of multidrug-resistant 
microorganisms, especially ESBL-producing species in 
urinary tract infection, medical institutions should make 
efforts to develop administrative and educational pro-
grams and to provide appropriate guidelines for the pre-
scription of antibiotics as well as urinary catheterization 
and to follow these guidelines strictly.
Conflicts of Interest
The authors have nothing to disclose.
REFERENCES
1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, 
Stamm WE. Guidelines for antimicrobial treatment of un-
complicated acute bacterial cystitis and acute pyelonephritis in 
women. Infectious Diseases Society of America (IDSA). Clin 
Infect Dis 1999;29:745-58. 
2. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for com-
munity-acquired urinary tract infection due to quinolone-re-
sistant E. coli. Infection 2008;36:41-5.
3. National Institute of Public Health and the Environment. Euro-
pean Antimicrobial Resistance Surveillance System (EARSS) an-
nual report 2008. Bilthoven: The Institue; 2009.
4. Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, 
Sahm DF. Prevalence of antimicrobial resistance among urinary 
tract pathogens isolated from female outpatients across the US 
in 1999. Int J Antimicrob Agents 2001;18:121-7. 
5. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, 
Palatnik LP, et al. Antibiotic resistance in outpatient urinary iso-
lates: final results from the North American Urinary Tract 
Infection Collaborative Alliance (NAUTICA). Int J Antimicrob 
Agents 2005;26:380-8.
6. Neu HC. The crisis in antibiotic resistance. Science 1992;257: 
1064-73.
7. Baraff LJ, Ablon WD. Cefaclor versus ampicillin for outpatient 
treatment of urinary tract infections. Am J Emerg Med 1984;2: 
327-30. 
8. Naber KG. Cefotaxime in urinary tract infections. Infection 
1989;17:425-8. 
9. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable 
resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime 
in clinical isolates of Klebsiella pneumoniae and Serratia mar-
cescens. Infection 1983;11:315-7. 
10. Bush K, Jacoby GA, Medeiros AA. A functional classification 
scheme for beta-lactamases and its correlation with molecular 
structure. Antimicrob Agents Chemother 1995;39:1211-33. 
11. Coque TM, Baquero F, Canton R. Increasing prevalence of 
ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 
2008;13.
12. Stamm WE. Catheter-associated urinary tract infections: epi-
demiology, pathogenesis, and prevention. Am J Med 1991;91: 
65S-71. 
13. National Nosocomial Infections Surveillance System. National 
Nosocomial Infections Surveillance (NNIS) System Report, data 
summary from January 1992 through June 2004, issued October 
2004. Am J Infect Control 2004;32:470-85.
14. Ryu KH, Kim MK, Jeong YB. A recent study on the antimicrobial 
sensitivity of the organisms that cause urinary tract infection. 
Korean J Urol 2007;48:638-45.
15. Lee SJ, Lee SD, Cho IR, Sim BS, Lee JG, Kim CS, et al. Antimicro-
bial susceptibility of uropathogens causing acute uncomplicated 
cystitis in female outpatients in South Korea: a multicentre study 
in 2002. Int J Antimicrob Agents 2004;24(Suppl 1):S61-4. 
16. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance 
among uropathogens causing acute uncomplicated cystitis in fe-
male outpatients in South Korea: a multicentre study in 2006. Int 
J Antimicrob Agents 2008;31(Suppl 1):S15-8.
17. Lee SJ. Current status of antimicrobial resistance among bacte-
rial pathogens causing urinary tract infection in Korea. Korean 
J UTII 2009;4:37-44. 
18. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance 
study in Europe and Brazil on clinical aspects and Antimicrobial 
Resistance Epidemiology in Females with Cystitis (ARESC): im-
plications for empiric therapy. Eur Urol 2008;54:1164-75. 
19. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility 
of extended-spectrum beta-lactamase-producing Escherichia 
coli and Klebsiella pneumoniae in a general hospital. Ann Saudi 
Med 2005;25:239-42.
20. Rodriguez-Bano J, Pascual A. Clinical significance of extended- 
spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008;6: 
671-83. 
21. Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana 
S, et al. Risk factors for community-onset urinary tract infections Korean J Urol 2010;51:492-497
Clinical Features of ESBL-Producing Uropathogens 497
due to Escherichia coli harbouring extended-spectrum beta- 
lactamases. J Antimicrob Chemother 2006;57:780-3. 
22. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz 
A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: 
predictive factors for isolation of an antibiotic-resistant strain 
and their impact on the outcome. J Antimicrob Chemother 2009; 
63:568-74. 
23. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, 
Timurkaynak F, et al. Risk factors for extended-spectrum beta- 
lactamase positivity in uropathogenic Escherichia coli isolated 
from community-acquired urinary tract infections. Clin Microbiol 
Infect 2010;16:147-51. 
24. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez 
L, Muniain MA, Perea EJ, et al. Epidemiology and clinical fea-
tures of infections caused by extended-spectrum beta-lacta-
mase-producing Escherichia coli in nonhospitalized patients. J 
Clin Microbiol 2004;42:1089-94.
25. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare 
Infection Control Practices Advisory Committee. Management of 
multidrug-resistant organisms in health care settings, 2006. Am 
J Infect Control 2007;35(10 Suppl 2):S165-93.
26. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC 
Project Group. Outpatient antibiotic use in Europe and associa-
tion with resistance: a cross-national database study. Lancet 
2005;365:579-87. 
27. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, 
et al. Infectious Diseases Society of America guidelines for the di-
agnosis and treatment of asymptomatic bacteriuria in adults. 
Clin Infect Dis 2005;40:643-54. 
28. Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosoco-
mial urinary tract infection. Am J Epidemiol 1986;124:977-85. 
29. Bukhari SS, Sanderson PJ, Richardson DM, Kaufman ME, 
Aucken HM, Cookson BD. Endemic cross-infection in an acute 
medical ward. J Hosp Infect 1993;24:261-71. 
30. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, 
Tambyah PA, Naber KG. European and Asian guidelines on man-
agement and prevention of catheter-associated urinary tract 
infections. Int J Antimicrob Agents 2008;31(Suppl 1):S68-78.